Reuters logo
BRIEF-Bausch + Lomb and Nicox announces FDA approval of Vyzulta
November 2, 2017 / 8:25 PM / a month ago

BRIEF-Bausch + Lomb and Nicox announces FDA approval of Vyzulta

Nov 2 (Reuters) - Valeant Pharmaceuticals International Inc

* Bausch + Lomb and Nicox announce FDA approval of Vyzulta™ (latanoprostene Bunod Ophthalmic Solution), 0.024%

* Valeant - ‍co’s wholly owned subsidiary, Bausch + Lomb and Nicox S.A announced FDA approved NDA for Vyzulta​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below